BOSTON, June 12, 2026 (GLOBE NEWSWIRE) — CervoMed Inc. (NASDAQ: CRVO), a clinical-stage biotechnology company developing treatments for age-related brain disorders (CervoMed or the Company), today announced that Company management will participate in a fireside chat and one-on-one investor meetings at the H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit, being held virtually on Monday, June 15, 2026. Presentation DetailsFormat: Fireside ChatDate: Monday, June 15, 2026Time: 7:00 – 7:30 AM ETWebcast Link: https://journey.ct.events/view/9162603c-eb01-4cb3-85b7-36814fad7928 The webcast of the fireside chat will be accessible in the Investor section of the CervoMed website https://www.cervomed.com/. About CervoMedCervoMed is a clinical-stage company developing treatments for age-related brain disorders. Its lead drug candidate,...

The partnership gives Exodus customers one-tap access to trading 200+ tokenized stocks and ETFs OMAHA, Neb., June 12, 2026 (GLOBE NEWSWIRE) — Exodus Movement, Inc. (NYSE American: EXOD) (“Exodus”) today announced the launch of Exodus Markets in partnership with Ondo Finance, a leader in tokenized assets, giving customers the ability to buy and sell more than 200 tokenized stocks, ETFs, and real-world assets directly on Solana through Exodus. Exodus Markets is the latest step in Exodus’ expansion from a self-custodial wallet into a complete financial platform that lets customers trade, spend, send, earn rewards, and manage money in one app. “Tokenized stocks are one of the most important developments in modern finance,” said JP Richardson, CEO and Co-founder of Exodus. “For the first time, our customers can trade and hold...

NEW YORK, June 12, 2026 (GLOBE NEWSWIRE) — OTC Markets Group Inc. (OTCQX: OTCM), operator of regulated markets for trading 12,000 U.S. and international securities, today announced Tesoro Gold Ltd (ASX: TSO; OTCQX: TSORF), a company focused on exploring gold assets with the potential to be district-scale mining projects, has qualified to trade on the OTCQX® Best Market. Tesoro Gold Ltd upgraded to OTCQX from the OTCQB® Venture Market. Tesoro Gold Ltd begins trading today on OTCQX under the symbol “TSORF.” U.S. investors can find current financial disclosure and Real-Time Level 2 quotes for the company on www.otcmarkets.com. The OTCQX Market is designed for established, investor-focused U.S. and international companies. To qualify for OTCQX, companies must meet high financial standards, follow best practice corporate governance,...

HOUSTON, June 12, 2026 (GLOBE NEWSWIRE) — Fervo Energy Company (“Fervo” or the “Company”) (NASDAQ: FRVO), a leading technology-enabled independent power producer of Enhanced Geothermal Systems (EGS), today announced that it will release first quarter 2026 financial and operational results before the market opens on Monday, June 22, 2026. The Company will host a webcast and conference call that same day at 10:00 a.m. ET (9:00 a.m. CT) to discuss the results. A live webcast of the conference call will be available in the “Events” section of the Company’s investor relations website at ir.fervoenergy.com. To participate in Q&A on the call, register here to receive the dial-in information and a unique PIN. A replay of the call will be available shortly after the conclusion of the live webcast. ABOUT FERVO Fervo is a modern power...

TORONTO, June 12, 2026 (GLOBE NEWSWIRE) — Xtract One Technologies (TSX: XTRA)(OTCQX: XTRAF)(FRA: 0PL) (“Xtract One” or the “Company”), a leading technology-driven threat detection and security solution that prioritizes the patron access experience by leveraging AI, today announced that it will participate in the upcoming Planet MicroCap Showcase Conference in Las Vegas on June 17 and 18, 2026. Management will provide a general presentation, to be webcast live, on June 17 at 1:00 pm Pacific Time and then host one-on-one meetings with investors all day on June 18. Individuals attending the conference are encouraged to contact Planet MicroCap directly for meeting availability. About Xtract One Xtract One Technologies is a leading technology-driven threat detection and security solution leveraging AI to provide seamless and secure...

Village Farms Launches Pure Sunfarms Pink Kush Cured Resin VapeCanada’s all-time number one strain now available as a true-to-flower cured resin vape.Canada’s all-time number one strain now available as a true-to-flower cured resin vape Launch positions Pure Sunfarms’ iconic Pink Kush in Canada’s fastest-growing cannabis category DELTA, British Columbia, June 12, 2026 (GLOBE NEWSWIRE) — Village Farms International, Inc. (“Village Farms” or the “Company”) (NASDAQ: VFF) today announced the launch of the Pure Sunfarms Pink Kush Cured Resin 510 Vape, bringing Canada’s all-time number one selling strain into the fastest-growing category of the Canadian cannabis market. Pure Sunfarms’ Pink Kush holds the distinction of being the all-time top-selling strain across major Canadian markets for five years running,1 making it one...

Responder rate of 57% at one year in open-label extension (OLE) comparable to 63% at 12 weeks in Phase 2 Avail™ trial Results consistent with restoration of systemic PTH activity through serum calcium normalization, reduction of urine calcium excretion, restoration of bone metabolism and increase of eGFR (a measure of kidney function) High retention rate with 90% of patients entering the OLE remaining in the study at one year Canvuparatide was generally well tolerated with no new safety signals during the OLE PK supports once-weekly dosing, with low peak-to-trough ratio and stable exposure Phase 3 pivotal trial remains on track to initiate in Q3 2026 Company to host conference call today at 8:00 a.m. ET CARMEL, Ind. and BURLINGTON, Mass., June 12, 2026 (GLOBE NEWSWIRE) — MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage...

TORONTO, June 12, 2026 (GLOBE NEWSWIRE) — illumin Holdings Inc. (TSX: ILLM and OTCQB: ILLMF) (“illumin” or the “Company”), the advertising technology platform that enables you to win your next customer, today announced that at its annual general meeting of shareholders held on June 11, 2026 (the “Meeting”), all director nominees proposed by the management of the Corporation were elected as directors of the Corporation, as follows:Nominee Votes “For” % Votes For Votes “Against” % Votes AgainstSheldon Pollack 14,257,496 93.849% 934,510 6.151%David Andrews 14,745,609 97.062% 446,397 2.938%Bruce Barker 14,212,007 93.549% 979,999 6.451%Tal Hayek 14,970,403 98.541% 221,603 1.459%Paul Khawaja 14,410,161 94.854% 781,845 5.146%In addition, the other items of business at the Meeting, being the...

Oral presentation at JDA features new data from the KT-621 Phase 1 study in healthy Japanese adults, with safety and PK/PD results consistent with previously reported KT-621 clinical studies  KT-621 parallel Phase 2b trials, BROADEN2 in atopic dermatitis and BREADTH in asthma, ongoing with data expected by mid-2027 and late 2027, respectively WATERTOWN, Mass., June 12, 2026 (GLOBE NEWSWIRE) — Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced that the results from the Phase 1 study of KT-621, its first-in-class, oral STAT6 degrader, in healthy Japanese adults were shared in an oral presentation at the Japanese Dermatological Association (JDA) Annual Meeting being held June 11-14, 2026, in...

— Growing body of ORLADEYO® clinical data and real-world evidence demonstrates consistent reductions in HAE attack burden and healthcare utilization across diverse patient populations — New post hoc analysis of Phase 1b/2 ALPHA-STAR study of investigational navenibart demonstrates consistent reductions in HAE attack rates across patient subgroups, supporting ongoing Phase 3 evaluation as a potential long-acting therapeutic option for the broad HAE population RESEARCH TRIANGLE PARK, N.C., June 12, 2026 (GLOBE NEWSWIRE) — BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced new clinical data and real-world evidence for ORLADEYO® (berotralstat), the first and only targeted oral prophylactic therapy for patients with hereditary angioedema (HAE) aged 2 and older, in addition to new data from the Phase 1b/2 multicenter, dose-ranging,...